Industry-Sponsored Symposium - Managing Effects of ACLF and Portal Hypertension: Variceal Bleeding, Respiratory and Renal Disease in Patients with Cirrhosis

Paul Y. Kwo, MD, FACG, Robert S. Brown, Jr., MD, MPH, FACG, Nancy S. Reau, MD, FACG

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Acute-on-Chronic Liver Failure (ACLF) typically describes a patient with underlying cirrhosis experiencing an acute insult such as infection in the context of intense systemic inflammation, accompanied by single- or multi-organ failure, that significantly increases the risk of 28-day mortality. Portal hypertension (PH) is one of the earliest and most significant complications of cirrhosis, resulting from increased intrahepatic resistance combined with increased portal and hepatic arterial blood flow. Clinically significant PH, identified by a hepatic venous pressure gradient >10mmHg, predicts the development of variceal hemorrhage, hepatic encephalopathy, ascites, and hepatorenal syndrome, all hallmarks of decompensation and multi-organ failure. This symposium will discuss the continuum of care of patients with chronic liver disease progressing to ACLF, and effective clinical decision-making by the gastroenterology team as the disease progresses.

Open to all ACG 2022 attendees, industry-sponsored symposia provide additional educational opportunities. These programs are independent of the ACG 2022 Annual Scientific Meeting and Postgraduate Course programs. ACG is not the continuing medical education provider of these programs. For more information, see the company sponsor.